Use of Antipsychotics for the Treatment of Behavioral Symptoms of Dementia

Journal of Clinical Pharmacology

Volumn 56, Issue 9, 2016, Pages 1048-1057

  Greenblatt, H Karl ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antipsychotics; behavioral symptoms; dementia; nursing homes

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABINOID; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DEXTROMETHORPHAN; FLUPHENAZINE; GALANTAMINE; HALOPERIDOL; LOXAPINE; MIBAMPATOR; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PRAZOSIN; PROMAZINE; QUETIAPINE; QUINIDINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE;

BEHAVIOR DISORDER; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; HYPERPROLACTINEMIA; MENTAL DISEASE; META ANALYSIS (TOPIC); MORTALITY; MORTALITY RISK; PHOTOTHERAPY; PNEUMONIA; PSYCHOSOCIAL CARE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOCIAL INTERACTION; SUDDEN CARDIAC DEATH; SUDDEN DEATH; TORSADE DES POINTES; TREATMENT DURATION; TREATMENT OUTCOME; BEHAVIOR; CLINICAL TRIAL (TOPIC); NURSING HOME; PATIENT CARE; PROCEDURES; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; CLINICAL TRIALS AS TOPIC; DEMENTIA; HUMANS; NURSING HOMES; PATIENT-CENTERED CARE; TREATMENT OUTCOME;

EID: 84988948795     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.731     Document Type: Review

References (88)

1. 2014 Alzheimer's disease: Facts and figures. 2014 http://www.alz.org/delval/documents/facts2014_full_report.pdf. Accessed July 18, 2015.
2. Gnanasekaran G. “Sundowning” as a biological phenomenon: current understandings and future directions: an update. Aging Clin Exp Res. 2015 [Epub ahead of print].
3. Bachman D, Rabins P. “Sundowning” and other temporally associated agitation states in dementia patients. Annu Rev Med. 2006;57:499–511.
4. Khachiyants N, Trinkle D, Son SJ, Kim KY. Sundown syndrome in persons with dementia: an update. Psychiatry Investig. 2011;8(4):275–287.
5. Alzheimer's disease 2013 http://www.cdc.gov/nchs/fastats/alzheimers.htm. Accessed July 18, 2015.
6. Stevenson DG, Decker SL, Dwyer LL, et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psychiatry. 2010;18(12):1078–1092.
7. Hendren J. 3 nursing home patients killed by ‘chemical restraints.’ ABC World News, http://abcnews.go.com/WN/abc-world-news-deadly-chemical-restraints-kill-california/story?id=9483981. Accessed January 5, 2010.
8. Bookman T. The battle against ‘chemical restraints’ inside nursing homes. New Hampshire Public Radio, http://nhpr.org/post/battle-against-chemical-restraints-inside-nursing-homes. Accessed February 4, 2013.
9. Jensen T. Chemical restraints: anti-psychotic meds given to elderly despite warnings. http://legacy.abc10.com/story/news/investigations/2015/06/17/45-area-nursing-homes-rate-below-average-for-the-use-of-antipsychotic-drugs/71258022/
10. Corbett A, Burns A, Ballard C. Don't use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ. 2014;349:g6420.
11. Berenson A. Lilly considers $1 billion fine to settle case. New York Times, January 31, 2008.
12. Wilson D. Side effects may include law suits. New York Times, October 2, 2010.
13. Rodwin MA. Rooting out institutional corruption to manage inappropriate off-label drug use. J Law Med Ethics. 2013;41(3):654–664.
14. Berns A. Dementia and antipsychotics: a prescription for problems. J Leg Med. 2012;33(4):553–569.
15. Mossman D, Steinberg JL. Promoting, prescribing, and pushing pills: Understanding the lessons of antipsychotic drug litigation. Mich State Univ J Med Law. 2009;8:263–334.
16. Finkel SI. Psychogeriatrics, nursing homes, and lawsuits. Int Psychogeriatr. 1997;9(2):109–113.
17. Medicare atypical antipsychotic drug claims for elderly nursing home residents. Department of Health and Human Services, Office of Inspector General. OEI-07-08-00150. http://oig.hhs.gov/oei/reports/oei-07-08-00150.pdf. Accessed May 2011.
18. Meeks TW, Jeste DV. Beyond the Black Box: what is the role for antipsychotics in dementia? Curr Psychiatry. 2008;7(6):50–65.
19. Dementia in the long term care setting. Guideline summary NGC-9847. U. S. Department of Health & Human Services, Agency for Healthcare Research and Quality. http://www.guideline.gov/content.aspx?id=45525
20. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Guideline summary NGC-9359. U. S. Department of Health & Human Services, Agency for Healthcare Research and Quality. http://www.guideline.gov/content.aspx?id=38470
21. Best practice guideline for accommodating and managing behavioral and psychological symptoms of dementia in residential care. Ministry of Health, Province of British Columbia, Canada. http://www.health.gov.bc.ca/library/publications/year/2012/bpsd-guideline.pdf. Accessed October 25, 2012.
22. Guidance CG-Dementia: Supporting people with dementia and their carers in health and social care. 42. National Institute for Health and Care Excellence, United Kingdom. https://www.nice.org.uk/guidance/cg42/resources/dementia-supporting-people-with-dementia-and-their-carers-in-health-and-social-care-975443665093. Accessed April 2014.
23. Assessment and management of people with behavioral and psychological symptoms of dementia. New South Wales (Australia) Ministry of Health. https://www.ranzcp.org/Files/Publications/A-Handbook-for-NSW-Health-Clinicians-BPSD_June13_W.aspx. Accessed May 2013.
24. Mollot TJ, Butler D. Federal requirements & regulatory provisions relevant to dementia care & the use of antipsychotic drugs. The Long Term Care Community Coalition. 2013. http://www.ltccc.org/publications/documents/ltccc-antipsychotic-drugs-oversight-ftags-mar2013.pdf
25. Policy statement: Use of antipsychotic medications in nursing facility residents. American Society of Consultant Pharmacists. https://www.ascp.com/sites/default/files/ASCP-antipsychotics-statement.pdf
26. Dementia care in nursing homes. Centers for Medicare and Medicaid Services, Department of Health and Human Services, Center for Clinical Standards and Quality, Survey and Certification Group. S&C: 13-35-NH. https://www.cms.gov/medicare/provider-enrollment-and-certification/surveycertificationgeninfo/downloads/survey-and-cert-letter-13-35.pdf. Accessed May 24, 2013.
27. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369.
28. Gareri P, De Fazio P, Manfredi VG, De Sarro G. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol. 2014;34(1):109–123.
29. Madhusoodanan S, Ting MB. Pharmacological management of behavioral symptoms associated with dementia. World J Psychiatry. 2014;4(4):72–79.
30. Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr. 2010;22(3):346–372.
31. Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245–255.
32. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308(19):2020–2029.
33. Kales HC, Gitlin LN, Lyketsos CG, et al. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–769.
34. Corbett A, Husebo B, Malcangio M, et al. Assessment and treatment of pain in people with dementia. Nat Rev Neurol. 2012;8(5):264–274.
35. Testad I, Corbett A, Aarsland D, et al. The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review. International Psychogeriatrics. 2014;26(7):1083–1098.
36. Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014;205(6):436–442.
37. Antonsdottir IM, Smith J, Keltz M, Porsteinsson AP. Advancements in the treatment of agitation in Alzheimer's disease. Expert Opin Pharmacother. 2015;16(11):1649–1656.
38. Panza F, Solfrizzi V, Seripa D, et al. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease. Expert Opin Pharmacother. 2015;16(17):2581–2588.
39. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–691.
40. Freund-Levi Y, Bloniecki V, Auestad B, et al. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. Dement Geriatr Cogn Disord. 2014;38(3-4):234–244.
41. Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer Disease dementia: A randomized clinical trial. JAMA. 2015;314(12):1242–1254.
42. Chiu Y, Bero L, Hessol NA, Lexchin J, Harrington C. A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy. 2015;119(6):802–813.
43. Yury CA, Fisher JE. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother Psychosom. 2007;76(4):213–218.
44. Dutcher SK, Rattinger GB, Langenberg P, et al. Effect of medications on physical function and cognition in nursing home residents with dementia. J Am Geriatr Soc. 2014;62(6):1046–1055.
45. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525–1538.
46. Barak Y, Plopski I, Tadger S, Paleacu D. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: A randomized double-blind pilot study. Int Psychogeriatr. 2011;23(9):1515–1519.
47. Ma H, Huang Y, Cong Z, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: A meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42(3):915–937.
48. Wang J, Yu JT, Wang HF, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2015;86(1):101–109.
49. Tan L, Tan L, Wang HF, et al. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis. Alzheimers Res Ther. 2015;7(1):20.
50. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm. 2012;18(5 Suppl B):s1–s20.
51. Gareri P, Cotroneo A, Lacava R, et al. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). Arch Gerontol Geriatr Suppl. 2004;(9):207–215.
52. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. April 2005 http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053171.htm. Accessed July 21, 2015.
53. Lester P, Kohen I, Stefanacci RG, Feuerman M. Antipsychotic drug use since the FDA black box warning: survey of nursing home policies. J Am Med Dir Assoc. 2011;12(8):573–577.
54. Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96–103.
55. Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999–2007. Arch Gen Psychiatry. 2011;68(2):190–197.
56. McIlroy G, Thomas SK, Coleman JJ. Second-generation antipsychotic drug use in hospital inpatients with dementia: the impact of a safety warning on rates of prescribing. J Pub Health. 2015;37(2):346–352.
57. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775–786.
58. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627–632.
59. Information for Healthcare Professionals: Conventional Antipsychotics. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm. June 2008 [Cited 21 July 2015].
60. Gardette V, Lapeyre-Mestre M, Coley N, et al. Antipsychotic use and mortality risk in community-dwelling Alzheimer's disease patients: evidence for a role of dementia severity. Curr Alzheimer Res. 2012;9(9):1106–1116.
61. Lopez OL, Becker JT, Chang YF, et al. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry. 2013;170(9):1051–1058.
62. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–1943.
63. Haupt M, Cruz-Jentoft A, Jeste D. Mortality in elderly dementia patients treated with risperidone. J Clin Psychopharmacol. 2006;26(6):566–570.
64. Trifiro G, Sultana J, Spina E. Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies. Drug Saf. 2014;37(7):501–520.
65. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225–235.
66. Trifiro G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res. 2009;59(1):1–12.
67. Hulshof TA, Zuidema SU, Ostelo RW, Luijendijk HJ. The mortality risk of conventional antipsychotics in elderly patients: a systematic review and meta-analysis of randomized placebo-controlled trials. J Am Med Dir Assoc. 2015;16(10):817–824.
68. Sahlberg M, Holm E, Gislason GH, Kober L, Torp-Pedersen C, Andersson C. Association of selected antipsychotic agents with major adverse cardiovascular events and noncardiovascular mortality in elderly persons. J Am Heart Assoc. 2015;4(9):e001666.
69. Ifteni P, Grudnikoff E, Koppel J, et al. Haloperidol and sudden cardiac death in dementia: autopsy findings in psychiatric inpatients. Int J Geriatr Psychiatry. 2015;30(12):1224–1229.
70. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):233–2341.
71. Jackson JW, Schneeweiss S, VanderWeele TJ, Blacker D. Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis. PLoS One. 2014;9(8):e105376.
72. Park Y, Franklin JM, Schneeweiss S, et al. Antipsychotics and mortality: adjusting for mortality risk scores to address confounding by terminal illness. J Am Geriatr Soc. 2015;63(3):516–523.
73. Kales HC, Kim HM, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71–79.
74. Setoguchi S, Wang PS, Alan Brookhart M, Canning CF, Kaci L, Schneeweiss S. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc. 2008;56(9):1644–1650.
75. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol. 2003;23(1):58–77.
76. Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol. 2002;450(1):37–41.
77. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drutherapy in psychiatric patients. Lancet. 2000;355(9209):1048–1052.
78. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158(11):1774–1782.
79. Cubeddu LX. Iatrogenic QT abnormalities and fatal arrhythmias: mechanisms and clinical significance. Curr Cardiol Rev. 2009;5(3):166–176.
80. Crumb WJ, Ekins S, Sarazan RD, et al. Effects of antipsychotic drugs on Ito, INa, Isus, IK1, and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res. 2006;23(6):1133–1143.
81. Yerrabolu M, Prabhudesai S, Tawam M, Winter L, Kamalesh M. Effect of risperidone on QT interval and QT dispersion in the elderly. Heart Dis. 2000;2(1):10–12.
82. Hasnain M, Vieweg WVR. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28(10):887–920.
83. Salvo F, Pariente A, Shakir S, et al. Sudden cardiac and sudden unexpected death related to antipsychotics: a meta-analysis of observational studies. Clin Pharmacol Ther. 2016;99(3):306–314.
84. Wu CS, Tsai YT, Tsai HJ. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J Am Heart Assoc. 2015;4(2):e001568.
85. Lin ST, Chen CC, Tsang HY, et al. Association between antipsychotic use and risk of acute myocardial infarction: a nationwide case-crossover study. Circulation. 2014;130(3):235–243.
86. Ishioka M, Yasui-Furukori N, Sugawara N, Furukori H, Kudo S, Nakamura K. Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers. Neuropsychiatr Dis Treat. 2015;11:477–484.
87. Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008;22(2, Suppl):46–55.
88. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596–608.